Lung Cancer in the Netherlands-Reference-Cited by-同舟云学术

Lung Cancer in the Netherlands

Published:2021-03 Issue:3 Volume:16 Page:355-365
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hendriks Lizza E.L.,Dingemans Anne-Marie C.,De Ruysscher Dirk K.M.,Aarts Mieke J.,Barberio Lidia,Cornelissen Robin,Hartemink Koen J.,van den Heuvel Michel,Schuuring Ed,Smit Hans J.M.,van der Wekken Antonie J.,Smit Egbert F.

Funder

Boehringer Ingelheim

Pfizer

Genentech

Amgen Nederland

Merck Sharp and Dohme

Janssen Pharmaceuticals

AstraZeneca

GlaxoSmithKline

Takeda Pharmaceutical Company

Ministeriet Sundhed Forebyggelse

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Reduced lung-cancer mortality with volume CT screening in a randomized trial;de Koning;N Engl J Med,2020

3. Who treats lung cancer? Results from a global survey;Komiya;Respir Investig,2017

4. Implementation of novel molecular biomarkers for non-small cell lung cancer in the Netherlands: how to deal with increasing complexity;van den Broek;Front Oncol,2019

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012–2021);European Journal of Cancer;2024-09

2. An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations;European Journal of Cancer;2024-09

3. Changes in Global Quality of Life after treatment with immune checkpoint inhibitors in patients with advanced stage lung cancer in the Netherlands – a 2015-2021 cohort study;2024-04-30

4. Strengths and challenges in current lung cancer care: Timeliness and diagnostic procedures in six Dutch hospitals;Lung Cancer;2024-03

5. Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors;Lung Cancer;2023-08